Idiopathic Pulmonary Fibrosis

Latest News in Idiopathic Pulmonary Fibrosis

May 19, 2025

Idiopathic Pulmonary Fibrosis (IPF): Global Clinical Trials Landscape – Clinical Leader

May 18, 2025

IMVARIA Reports Multi-Site Clinical Experience With FDA-Authorized AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025 – Business Wire

May 15, 2025

ITGAV, a specific biomarker associated with the pathogenesis of idiopathic pulmonary fibrosis – Nature

May 15, 2025

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) – PR Newswire

May 14, 2025

Prediction model of mitochondrial energy metabolism related genes in idiopathic pulmonary fibrosis and its correlation with immune microenvironment – Nature

104 Active Idiopathic Pulmonary Fibrosis Clinical Trials

As of June 21, 2025

Source: clinicaltrials.gov

LOCATE

CLINICAL TRIALS

BROWSE

FDA-approved DRUGS

WHAT IS

CONGRESS DOING?